NXE-0048149 is under clinical development by Nxera Pharma and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs for Schizophrenia have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NXE-0048149’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NXE-0048149 overview
Nxera Pharma overview
Nxera Pharma, formerly Sosei Group Corp, is a biopharmaceutical company that develops drugs. The company’s pipeline products include CCR6 Antagonist, Muscarinic M4 Agonist, MC4 Antagonist, GLP-1 agonist, Dual Muscarinic M1 and M4 Agonists, Muscarinic M4-preferring agonist, Muscarinic M1 Agonist, OX2 Agonist, mGlu5 NAM, CXCR4 mAb, PAR2 Peptide, AI Augmented Drug Discovery, Gut-Brain Axis Drug Discovery. Its medical products include ultibro, seebri, enerzair, breezhaler, pivlaz and oravi. The company operates in Japan, South Korea, Ireland and the UK. Nxera Pharma is headquartered in Chiyoda-ku, Tokyo, Japan.
For a complete picture of NXE-0048149’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
